UK markets close in 6 hours 7 minutes
  • FTSE 100

    7,250.40
    +41.59 (+0.58%)
     
  • FTSE 250

    19,317.43
    +193.72 (+1.01%)
     
  • AIM

    903.36
    +7.09 (+0.79%)
     
  • GBP/EUR

    1.1618
    -0.0000 (-0.00%)
     
  • GBP/USD

    1.2293
    +0.0023 (+0.19%)
     
  • BTC-GBP

    17,436.82
    -28.15 (-0.16%)
     
  • CMC Crypto 200

    467.70
    +13.80 (+3.04%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • DOW

    31,500.68
    +823.28 (+2.68%)
     
  • CRUDE OIL

    107.03
    -0.59 (-0.55%)
     
  • GOLD FUTURES

    1,840.10
    +9.80 (+0.54%)
     
  • NIKKEI 225

    26,871.27
    +379.30 (+1.43%)
     
  • HANG SENG

    22,229.52
    +510.46 (+2.35%)
     
  • DAX

    13,264.50
    +146.37 (+1.12%)
     
  • CAC 40

    6,099.57
    +26.22 (+0.43%)
     

Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Mirati Therapeutics MRTX announced that it has filed a marketing authorization application (MAA) in the European Union (EU) for its KRAS-G12C inhibitor adagrasib for non-small cell lung cancer (NSCLC).

The MAA filed with the European Medicines Agency (EMA) seeks approval for adagrasib as a potential treatment for patients with KRAS-G12C-mutated NSCLC. The patients must have received at least one prior systemic therapy.

MRTX already submitted a new drug application (NDA) with the FDA seeking approval under the accelerated pathway for adagrasib for the above-mentioned indication. In February, Mirati announced that the FDA accepted the NDA and set a PDUFA action date of Dec 14, 2022, for the same.

Shares of Mirati have plunged 59.4% in the year-to-date period compared with the industry’s 24.1% decline.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

The filings in both the United States and the EU are based on positive top-line data from the phase II potentially registration-enabling monotherapy-cohort of the KRYSTAL-1 study, evaluating adagrasib for the above-mentioned indication. Data from the study was announced last Sepetmber. In the study, treatment with adagrasib led to an objective response rate of 43% and a disease control rate of 80% as of Jun 15, 2021.

Currently, there are very limited options available to patients suffering KRAS-G12C mutated NSCLC. A potential approval of adagrasib will provide Mirati with its first marketed drug and the patients with a new therapeutic option.

Mirati’s adagrasib, if approved, will face stiff competition from Lumakras, a KRAS-G12C inhibitor, marketed by Amgen AMGN. AMGN received accelerated approval for Lumakras as a second-line treatment for locally advanced or metastatic NSCLC from the FDA last May. Earlier in January this year, Amgen also gained approval for the drug in Europe for a similar indication. The drug has shown robust launch uptake since its approval, with Amgen recording revenues worth $62 million from its sales in first-quarter 2022.

The KRYSTAL-1 study is also evaluating adagrasib in multiple cohorts in combination with other therapies. These include a combo therapy of adagrasib with Merck’s MRK Keytruda for first-line NSCLC, a combination of adagrasib plus Boehringer Ingelheim’s Gilotrif (afatinib) for advanced NSCLC and adagrasib combined with Bristol-Myers’ BMY Erbitux for second-line colorectal cancer (CRC).

Preliminary data from the adagrasib plus Merck’s Keytruda cohort demonstrated that the combination achieved a 100% disease control rate, with all seven patients exhibiting tumor regression ranging from 37% to 92% as of Oct 21, 2021.

Mirati is also pursuing a broad combination development program for adagrasib beyond the combinations with Merck’s Keytruda and Bristol-Myers’ Erbitux. These include combinations with SHP2, SOS1 or CDK 4/6 inhibitors.

Both Opdivo and Keutruda are key drivers for Bristol Myers and Merck’s top lines, respectively. During the first quarter of 2022, Bristol Myers recorded $1.9 billion from Opdivo sales while Merck recorded $4.8 billion from Keytruda sales.

Mirati Therapeutics, Inc. Price

Mirati Therapeutics, Inc. Price
Mirati Therapeutics, Inc. Price

Mirati Therapeutics, Inc. price | Mirati Therapeutics, Inc. Quote

Zacks Rank

Mirati currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting